TY - JOUR
T1 - Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis
T2 - analysis of the Optum EHR and commercial claims databases
AU - Dispenzieri, Angela
AU - Zonder, Jeffrey
AU - Hoffman, James
AU - Wong, Sandra W.
AU - Liedtke, Michaela
AU - Abonour, Rafat
AU - D’Souza, Anita
AU - Lee, Charlene
AU - Cote, Sarah
AU - Potluri, Ravi
AU - Ammann, Eric
AU - Tran, Nam Phuong
AU - Lam, Annette
AU - Nair, Sandhya
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Background: This study characterised real-world treatment patterns, clinical outcomes, and cost-of-illness in patients with light-chain (AL) amyloidosis. Methods: Data were extracted from the US-based Optum® EHR and Clinformatics® Data Mart (claims) databases (2008–2019) for patients newly diagnosed with AL amyloidosis and who initiated anti-plasma cell therapies. Healthcare resource utilisation (HCRU) and related costs were compared across lines of therapy (LOT). Incidences of cardiac and renal failure were evaluated using the Kaplan-Meier method. Results: About 1347 patients (EHR, n = 776; claims, n = 571) were included. Median age was 68 years; 56.8% were male. At initial diagnosis, 33.1% and 15.1% of patients had cardiac and renal failure, respectively. Most patients received bortezomib-containing treatment in LOT1 (69%); bortezomib-cyclophosphamide-dexamethasone was most common (26%). HCRU was similar across LOTs. Mean per-patient-per-month and per-patient-per-LOT costs were $19,343 and $105,944 for LOT1, $19,183 and $95,793 for LOT2, and $16,611 and $128,446 for LOT3, respectively. Costs were primarily driven by anti-plasma cell therapies, outpatient visits, and hospitalisations. The 5-year cardiac and renal failure rates following initial diagnosis were 64.5% and 39.0%, respectively. Conclusion: AL amyloidosis is associated with substantial costs and suboptimal outcomes, highlighting the need for new therapeutic approaches to prevent organ deterioration, and reduce disease burden.
AB - Background: This study characterised real-world treatment patterns, clinical outcomes, and cost-of-illness in patients with light-chain (AL) amyloidosis. Methods: Data were extracted from the US-based Optum® EHR and Clinformatics® Data Mart (claims) databases (2008–2019) for patients newly diagnosed with AL amyloidosis and who initiated anti-plasma cell therapies. Healthcare resource utilisation (HCRU) and related costs were compared across lines of therapy (LOT). Incidences of cardiac and renal failure were evaluated using the Kaplan-Meier method. Results: About 1347 patients (EHR, n = 776; claims, n = 571) were included. Median age was 68 years; 56.8% were male. At initial diagnosis, 33.1% and 15.1% of patients had cardiac and renal failure, respectively. Most patients received bortezomib-containing treatment in LOT1 (69%); bortezomib-cyclophosphamide-dexamethasone was most common (26%). HCRU was similar across LOTs. Mean per-patient-per-month and per-patient-per-LOT costs were $19,343 and $105,944 for LOT1, $19,183 and $95,793 for LOT2, and $16,611 and $128,446 for LOT3, respectively. Costs were primarily driven by anti-plasma cell therapies, outpatient visits, and hospitalisations. The 5-year cardiac and renal failure rates following initial diagnosis were 64.5% and 39.0%, respectively. Conclusion: AL amyloidosis is associated with substantial costs and suboptimal outcomes, highlighting the need for new therapeutic approaches to prevent organ deterioration, and reduce disease burden.
KW - AL amyloidosis
KW - Real-world treatment patterns
KW - burden of illness
KW - optum EHR
KW - optum claims
UR - http://www.scopus.com/inward/record.url?scp=85141209303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141209303&partnerID=8YFLogxK
U2 - 10.1080/13506129.2022.2137400
DO - 10.1080/13506129.2022.2137400
M3 - Article
C2 - 36282014
AN - SCOPUS:85141209303
SN - 1350-6129
VL - 30
SP - 161
EP - 168
JO - Amyloid
JF - Amyloid
IS - 2
ER -